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 Abstract 
 Purpose: The aim of this study was to evaluate the quality of care and interdisciplinary coop-
eration in the palliative treatment of colorectal cancer (CRC), including the associated costs. 
 Patients and Methods: 103 patients were enrolled from 13 institutions to reflect the existing 
clinical treatment reality and costs of palliative CRC treatment. We present the clinical out-
come of the patients and compare the results obtained in the 3 centers with double-figure 
recruitment numbers (centers A, B, and C).  Results: First-line treatment with 5-fluorouracil 
monotherapy was applied in exceptional cases. The regular treatment method comprised ei-
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ther an irinotecan- (30%) or an oxaliplatin-based regimen (32%). Biological agents were add-
ed to the treatment of 33 patients (32%). The median overall survival (OS) of the total patient 
collective was 25 months. The OS differed significantly in 2 out of the 3 centers, ranging be-
tween 27 and 11 months. Secondary metastasis resections were performed in 26% of the to-
tal patient collective. The center with the most favorable outcome results also had the lowest 
costs for palliative treatment and care, including the lowest drug costs.  Conclusion: A com-
bined chemotherapy treatment was the rule. Concerning biological agents, a significant lack 
of their application in first-line treatment and the quality of interdisciplinary cooperation have 
to be addressed.  © 2014 S. Karger AG, Basel 
 Introduction 
 Colorectal cancer (CRC) is the second most common form of cancer in women and the 
third most common cancer in men: in 2008, the estimated worldwide incidence of CRC 
exceeded 1.2 million with a mortality rate of over 600,000  [1] . In Germany, CRC is one of the 
most common malignancies: more than 70,000 new cases and approximately 30,000 mortal-
ities are recorded each year  [2] . Metastasis at diagnosis is seen in about 20–25% of all CRCs 
 [2, 3] . Although recent studies have demonstrated substantial improvements in overall survival 
(OS) owing to the inclusion of new agents in palliative medicine treatment approaches  [4–7] 
and close interdisciplinary cooperation with the objective of secondary metastatic resection 
 [8] , CRC still poses a major problem in terms of healthcare policy and economics  [9] .
 The first version of the Interdisciplinary German S3 Guidelines for Diagnostics, Treatment 
and Follow-Up in CRC was published in 2004, with the objective of ensuring optimal care for 
all those affected  [2] . The IVOPAK (Integrated Care and Quality Control in Palliative Treatment 
of CRC) I study prospectively recorded both the results of palliative treatment of CRC as well 
as the costs thereof in terms of healthcare economics. Therefore, it reflects the current reality 
of palliative CRC treatment. Furthermore, the study demonstrates the extent to which the 
guidelines have been implemented across Northern Bavaria. Therapeutic procedures for 
palliative CRC treatment vary widely. The respective individual case should be presented to 
an interdisciplinary tumor board prior to the treatment initiation in order to define the 
potential therapeutic options  [2] .
 In the case of histologically proven distant metastases in the lungs or liver, the current 
CRC S3 guidelines published in 2008 recommend thoroughly different treatment options for 
primarily resectable liver and/or pulmonary metastases than they do for distant metastases 
in a palliative setting  [2] . If resectable pulmonary metastases are observed, curative metas-
tasis resection should be undertaken  [2] . Patients should be presented to specialized centers, 
where proven experts have experience with surgical oncology procedures  [2] . If primarily R0 
resectable liver metastases are detected, curative resection is equally recommended. The 
feasibility of this surgical procedure should be judged in advance by an experienced surgeon 
 [2] . In justified exceptional cases, neoadjuvant systemic treatment options might be considered 
 [2, 10] . Definitively nonresectable distant metastases represent a different situation: if 
primarily nonresectable liver metastases are observed, a systemic treatment should be 
started  [2] . In such cases, regular evaluations to assess the potential resectability of secondary 
metastases are of utmost importance  [2, 8, 11] .
 Prior to and shortly after the publication of the 2008 guidelines, targeted therapeutics 
(i.e. biological agents) were shown to result in incremental improvements in palliative 
treatment, thus offering new therapeutic options for first-line treatment  [4–7] . In several 
clinical studies, numerous inclusion and exclusion criteria amount to specific patient selec-
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tion. The results they generate, particularly the positive results, thus frequently do not reflect 
real treatment settings in daily clinical routine.
 The objective of the observational IVOPAK study was to prospectively record the real 
treatment setting in daily clinical routine and to assess and discuss the implementation of the 
current S3 guidelines in palliative treatment strategies. In the context of integrated healthcare 
strategies, the aspect of interdisciplinary cooperation – in terms of both secondary metastasis 
resection and treatment costs – was also considered and evaluated.
 Patients and Methods 
 Eligibility Criteria 
 The study was approved by the local ethics committee and met the standards laid down in the Helsinki 
Declaration of 1975 (in its current, revised form). Prior to the enrollment, written informed consent was 
obtained from all patients. Patients meeting the following inclusion criteria were eligible for enrollment in 
the study:
(1) diagnosis of histologically confirmed adenocarcinoma of the colon or rectum; 
 (2) Eastern Cooperative Oncology Group (ECOG) index  ≤ 2;
(3) definitively nonresectable metastases according to the decision of the respective oncological center, 
normally after presentation to the Erlangen University interdisciplinary tumor board (see definition of 
nonresectable metastases in metastatic CRC,  table 1 ); 
 (4) palliative chemonaive patients, and 
 (5) members of a specific statutory health insurance scheme (AOK Bayern).
 Treatment 
 The complete procedure of palliative and supportive treatment, including the interdisciplinary coop-
eration involved in CRC therapy, was performed in accordance with the principles of each ambulatory onco-
logical center, without any specific precepts or standards stipulated by the project leaders. Only the results, 
i.e. overall response rate (ORR), OS, progression-free survival (PFS), secondary metastasis resection and 
toxicity according to the National Cancer Institute of Common Toxicity Criteria (NCI-CTC) were evaluated 
and calculated. The costs of treatment and palliative care in German real-world settings were evaluated over 
the 2-year period following the onset of palliative chemotherapy  [9] from the perspective of the German 
statutory health insurance.
 Statistics 
 The Kaplan-Meier method was used to calculate OS and PFS. OS was defined as the time interval from 
the onset of palliative chemotherapy to death from any cause. The response was assessed according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0  [12] . At each treatment cycle, patients 
underwent clinical examination and laboratory assessment. Adverse events (according to the NCI-CTC 
version 2.0) and concomitant medication were recorded  [13] . PFS was defined as the time from the start of 
palliative chemotherapy to the first radiological or clinical observation of disease progression, or death from 
any cause. All variables were summarized by descriptive statistics. The 95% confidence intervals (CIs) were 
calculated in accordance with the Greenwood criteria  [14] .
Multiple distant metastases in more than one orga n and/or
Diffuse bilateral metastatic infiltration within a single 
organ (e.g. liver: invasion of the left and right branches 
of the hepatic artery or the portal vein, or of the three 
main branches of the hepatic vein) and/or
Distant metastases or local recurrence within the 
immediate proximity of a central blood vessel or the bile 
duct that would render curative resection unlikely
 Table 1.  Definition of primarily 
nonresectable distant metastases 
in CRC by the interdisciplinary 
tumor board of the Erlangen 
University Hospital
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 Results 
A total of 103 patients met the inclusion criteria and were enrolled in the study 
between February 2006 and November 2011. November 30, 2011 was defined as the 
cutoff date for the evaluation of patient data. A further 2 patients (2%) were defined as 
ineligible: 1 patient withdrew informed consent and 1 patient had the wrong statutory 
health insurance. Median follow-up was 23 months (range: 0–77). At the cutoff date, 93 out 
of the 103 patients (90%) had died and 10 patients (9%) showed no evidence of disease 
(NED).
 Patient Characteristics 
The main patient characteristics – both in terms of the total patient collective and subcat-
egorized into the patients at the centers A, B and C – are represented in  table 2 . The charac-
teristics of patients treated at these 3 centers were comparable ( table 2 ). The details of the 
regimens applied in first-line treatment and the frequency of their application, for both the 
entire patient cohort and subcategorized into the patients treated at the centers A, B and C, 
are shown in table 7.
 Multidisciplinary Cooperation 
 Presentation prior to Palliative Treatment 
 The presentation of the patients to the interdisciplinary tumor board prior to the onset 
of palliative treatment was as follows: total number 53/103 (51%), center A 37/37 (100%), 
center B 9/35 (26%) and center C 2/10 (20%) (χ 2 test: p < 0.001).
 Secondary Metastasis Resection after Downsizing by Means of First-Line Treatment 
The evaluation was performed for all cases in which an attempt to achieve a curative 
situation was undertaken and also for the patients with peritonectomy plus hyperthermic 
 Table 2. Patient characteristics
Total cohort
(n = 103)
Center A
(n = 37)
Center B
(n = 35)
Center C
(n = 10)
p
Age (max/median/min), years 87/70/20 87/70/22 80/69/37 79/73.5/42 0.447
Gender
Male
Female
68 (66)
35 (34)
24 (66)
13 (34)
21 (60)
14 (40)
7 (70)
3 (30)
0.853
Primary tumor location
Colon
Rectum
57 (55)
46 (45)
20 (55)
17 (45)
26 (73)
9 (27) 
3 (30)
7 (70)
0.033
Metastases
Synchronous
Metachronous
50 (49)
53 (51)
14 (38)
23 (62)
19 (54)
16 (46)
8 (80)
2 (20)
0.058
Liver-only metastases?
Yes
No
55 (53)
48 (47)
19 (51)
18 (49)
19 (55)
16 (46)
6 (60)
4 (40)
0.908
ECOG grade
0/1
2
90 (87)
13 (13)
32 (86)
5 (14)
30 (86)
5 (14)
9 (90)
1 (10)
1.0
Figures represent patient numbers with percentages in parentheses unless otherwise indicated.
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intraperitoneal chemotherapy or radiofrequency ablation, regardless of the residual tumor 
classification. Results are shown in table 7. In a further 8 out of 13 centers (61%) with a total 
of 10 enrolled patients (9%), neither presentation to the interdisciplinary tumor board 
(prior to the onset of first-line treatment) nor secondary metastasis resections were 
performed.
 Patient Group with Secondary Metastasis Resections (n = 27) 
 Of the patients with secondary metastasis resections, 21 out of 27 (77%) had liver-only 
metastases and 2/27 patients (7%) had lung-only metastases. In 4 out of 27 patients (14%), 
a combination of liver and lung or liver and peritoneal metastases was observed. Of the 27 
patients with secondary resections, 22 (81%) were described as having undergone R0 
resection; 10 of these 22 R0 resected patients (45%) had NED at the cutoff date, which equates 
to 40% (10/27) of all patients with secondary metastasis resections. Recurrence and subse-
quent death from progressive disease was observed in 15 of the 27 resected patients (55%).
 Toxicity in First-Line Treatment 
 The symptoms of toxicity experienced by the 103 patients during first-line treatment are 
listed in  table 3 . Gastrointestinal side effects, in particular severe diarrhea (CTC grade 3/4) 
predominated in 13 patients (13%; 95% CI: 6.2–19.0); severe nausea and vomiting were 
observed in 6 patients (6%; 95% Cl: 0.7–9.0). Severe hematological toxicity (CTC grade 3/4) 
was rare, with leukocytopenia being observed in 3 patients (3%; 95% CI: 0–6.2;  table 3 ). 
Treatment-induced deaths did not occur. Toxicity did not vary significantly between the 
centers A, B and C (data not shown), whereby low-grade toxicity in the form of dermatitis 
acneiform was observed at the center using cetuximab in first-line treatment.
 Overall Survival 
 OS in the total patient collective (n = 103) was 25 months (95% CI: 21–29;  fig. 1 ). Restricted 
to the centers A, B and C, OS times were 27 (95% CI: 23–32), 25 (95% CI: 17–33) and 11 
months (95% CI: 0–24) for centers A, B and C, respectively. OS differed significantly between 
 Table 3. Maximum toxicity experienced by all patients (n = 103) participating in the IVOPAK project
 Toxicity grade
 0 1 2 3 4
Anemia 93 (90) 5 (5) 4 (4) 1 (1) –
Leukocytopenia 76 (73) 14 (14) 10 (10) 3 (3) –
Neutropenia 92 (89) 6 (6) 5 (5) – –
Thrombocytopenia 95 (92) 2 (2) 4 (4) 2 (2) –
Stomatitis 100 (97) 1 (1) – 2 (2) –
Nausea 60 (58) 26 (25) 14 (14) 3 (3) –
Vomiting 78 (75) 13 (13) 9 (9) 2 (2) 1 (1)
Diarrhea 53 (51) 9 (9) 28 (27) 11 (11) 2 (2)
Hand-foot syndrome 89 (86) 5 (5) 6 (6) 3 (3) –
Alopecia 84 (81) 9 (9) 10 (9)
Peripheral sensory neuropathy 92 (89) 5 (5) 6 (6) – –
Hypertonia 99 (96) 1 (1) 1 (1) 2 (2) –
Dermatitis acneiform 97 (94) 3 (3) 3 (3) – –
Figures represent patient numbers with percentages in parentheses. Toxicity is graded according to the 
NCI-CTC. 
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centers A and C (p = 0.006;  fig. 2 ). When the OS of the patient group treated with a multimodal 
strategy (i.e. secondary metastasis resection after first-line treatment; n = 27; multimodal 
group) is compared to the OS of the patient group treated solely with sequential chemo-
therapy (n = 76; palliative group), highly significant differences (p < 0.001) were observed: 
OS times of 49 months (95% CI: 31–67) were achieved in the multimodal group compared to 
22 months (95% CI: 17–27) in the palliative group ( fig. 3 ).
 Progression-Free Survival 
 The median PFS following first-line treatment was 7 months (95% CI: 5–9) for the total 
patient collective (n = 103) as shown in  figure 4 . In the centers A, B and C, PFS rates amounted 
to 10 months (95% CI: 6–14), 8 months (95% CI: 4–12) and 4 months (95% CI: 3–4), respec-
tively. A significant difference in PFS is apparent between centers A and C (p = 0.001;  fig. 5 ). 
0
0.2
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0.6
0.8
1.0
0 12 24 36 48 60
Months
O
S
0
0.2
0.4
0.6
0.8
1.0
0 12 24 36 48 60
Months
O
S
Center A
Center B
Center C
 Fig. 1. Median OS: IVOPAK total 
patient collective (n = 103): 25 
months (95% Cl: 21–29 months). 
2-year OS 52.2%; 3-year OS 
30.7%; 5-year OS 14.5%. 
 Fig. 2. Median OS: patients of the 
3 study centers with double-fig-
ure recruitment numbers: center 
A (n = 37) 27 months (95% Cl: 23–
32 months); center B (n = 35) 25 
months (95% Cl: 17–33 months); 
center C (n = 10) 11 months (95% 
Cl: 0–24 months). 2-year OS 68/
51/20%; 3-year OS 34/34/20%; 
5-year OS 30/10/0%. p overall = 
0.013; p A vs. B = 0.214; p A vs. C = 
0.006; p B vs. C = 0.036. 
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When the median PFS of the group of patients who underwent secondary metastasis resection 
after first-line treatment (n = 27; multimodal group) is compared with the group of patients 
who had received a treatment based solely on sequential chemotherapy (n = 76; palliative 
group), the difference in PFS is highly significant (p < 0.001) and in favor of the multimodal 
patient group: 18 months (95% CI: 8–29) versus 6 months (95% CI: 5–7;  fig. 6 ).
 Treatment Costs 
 The total costs of palliative CRC treatment and care in the IVOPAK project have been 
evaluated and published previously  [9] . Costs for drugs – such as cytostatic agents, biologicals 
and biomodulators – represent the main cost drivers and constitute 70% of the total costs  [9] . 
In the centers A, B and C, drug costs constitute the main factor contributing to the total cost 
of palliative care during the first and second years of treatment ( table 4 ). The differences in 
0
0.2
0.4
0.6
0.8
1.0
0 12 24 36 48 60
Months
O
S
Multimodal group
Palliative group
0
0.2
0.4
0.6
0.8
1.0
0 12 24 36 48 60
Months
PF
S
 Fig. 3. Median OS: multimodal pa-
tient group (first-line treatment 
plus secondary metastasis resec-
tion) versus palliative patient 
group (sequential treatment): 
multimodal patient group (n = 
27) 49 months (95% Cl: 31–67 
months) and palliative patient 
group (n = 76) 22 months (95% 
Cl: 17–27 months). 2-year OS 
78/43%; 3-year OS 63/19%; 
5-year OS 46/0%. p < 0.001. 
 Fig. 4. Median PFS: total patient 
collective (n = 103): 7 months 
(95% Cl: 5–9 months). 1-year PFS 
32%; 2-year PFS 15%. 
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both total and drug costs were substantial between the abovementioned centers, particularly 
during the first year of palliative treatment ( table 4 ). The differences in drug costs between 
the 3 centers with more than 10 enrolled patients, itemized in terms of individual drug costs, 
are presented in  tables 5 and  6 . Drug costs vary significantly here too, not only during the first 
year of treatment but also during the second year. Possible causes and reasons for this are 
outlined in the discussion section.
 Response 
 The ORR, i.e. partial remission (PR) plus complete remission (CR), to first-line treatment 
was 38% (n = 39) for the total IVOPAK patient collective (n = 103). PR accounted for 37%
(n = 38) and radiological CR (according to imaging techniques) was observed in 1 patient 
(1%) after first-line treatment with the FOLFOX6 regimen. In a further 5 patients (5%), CR 
was achieved after radiological PR according to imaging techniques plus subsequent second-
0
0.2
0.4
0.6
0.8
1.0
0 12 24 36 48 60
Months
PF
S
Center A
Center BCenter C
0
0.2
0.4
0.6
0.8
1.0
0 12 24 36 48 60
Months
PF
S
Multimodal group
Palliative group
 Fig. 5. Median PFS: patients of
the 3 study centers with double-
figure recruitment numbers: cen-
ter A 10 months (95% Cl: 6–14 
months); center B 8 months (95% 
Cl: 4–12 months); center C 4 
months (95% Cl: 3–4 months).
p A vs. B = 0.032; p A vs. C = 0.001;
p B vs. C = 0.098. 
 Fig. 6. Median PFS: multimodal 
patient group (first-line treat-
ment plus secondary metastasis 
resection) versus palliative pa-
tient group (sequential treat-
ment): multimodal patient group 
(n = 27) 18 months (95% Cl: 8–29 
months) and palliative patient 
group (n = 76) 6 months (95% Cl: 
5–7 months). p < 0.001. 
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ary metastasis resection (multimodal procedure). Overall, the CR rate in the IVOPAK study 
reached 6%. The best response observed among the 6 patients who had received 5-fluoro-
uracil (5-FU) monotherapy as the first-line treatment was a stable disease situation.
 Discussion 
 In CRC, the treatment of histologically proven, primarily resectable distant liver and lung 
metastases differs distinctly from the treatment of distant metastases in a palliative situation 
 [2, 15, 16] .
 Numerous recent phase III studies on palliative first-line treatment have refrained from 
presenting a clear definition of nonresectable distant metastases of CRC as an inclusion 
criterion: the inclusion criteria ‘histologically proven metastatic colorectal adenocarcinoma’ 
 [4] and ‘untreated metastatic colorectal carcinoma’  [17] do not definitively exclude patients 
with primarily resectable distant metastases from enrollment into these palliative first-line 
studies. The study conducted by Watkins et al.  [16] confirms the resectability status as an 
important prognostic factor. Despite the same treatment regimen, i.e. XELOX, being applied 
in both groups of the latter study, the palliative patient collective (group A) had a median OS 
of 14.6 months, whereas this was 52.9 months in the patient group with primarily resectable 
distant metastases (group C)  [16] .
 Table 4. Total costs of palliative treatment and care at the 3 centers with double-figure recruitment numbers
Center A (n = 37) Center B (n = 35) Center C (n = 10) Variance analysis, centers
 mean costs SD mean costs SD mean costs SD A, B and C1
p value
A and B2
p value
Average costs year 1
Transport costs 545.66 1,759.78 205.15 212.66 0.00 0.00 0.33112 0.26349
Inpatient services 9,960.71 2,677.04 10,217.19 2,501.13 7,442.40 2,898.91 0.01395 0.68005
Preinpatient services 1,261.31 375.44 1,251.39 392.79 886.58 440.04 0.02402 0.91428
Emergency services 304.47 86.85 93.26 0.00 0.00 0.00 0.02235 0.02235
Outpatient services 0.00 0.00 1,652.80 880.48 1,144.82 798.22 0.00000 0.00000
Other services 0.00 0.00 7.92 22.80 0,00 0,00 0.07880 0.04767
Outpatient rehabilitation 5.42 15.32 0.00 0.00 0.00 0.00 0.07156 0.04374
Inpatient rehabilitation 237.96 820.76 10.58 62.57 0.00 0.00 0.19035 0.11133
Long-term and on-demand medication 453.65 480.79 366.38 402.48 832.24 1,284.70 0.16755 0.43234
Supportive medication 391.82 285.48 448.94 150.14 503.74 920.12 0.79245 0.66545
Medical supplies 108.29 170.15 0.00 0.00 6.19 7.34 0.00042 0.00053
Cytostatic agents/biological
agents/biomodulators 24,098.58 13,504.53 39,216.55 27,302.16 23,451.21 20,039.15 0.00821 0.00492
Average costs year 2
Transport costs 35.26 58.09 189.23 210.56 156.60 0.00 0.00395 0.00186
Inpatient services 7,303.94 3,131.68 6,812.58 3,242.87 5,511.59 4,558.43 0.63250 0.58830
Preinpatient services 1,193.27 546.63 1,115.72 564.07 894.08 790.42 0.66201 0.62379
Emergency services 249.94 106.74 0.00 0.00 279.78 0.00 0.78631 –
Outpatient services 0.00 0.00 1,162.19 826.69 0.00 0.00 0.00000 0.00000
Other services 0.00 0.00 10.04 29.04 0.00 0.00 0.22820 0.10373
Outpatient rehabilitation 3.80 18.98 3.96 19.38 0.00 0.00 0.97980 0.97709
Inpatient rehabilitation 0.00 0.00 107.96 400.75 0.00 0.00 0.40345 0.19989
Long-term and on-demand medication 369.73 444.06 286.76 307.82 502.33 374.55 0.57402 0.50565
Supportive medication 358.07 263.04 103.91 0.00 551.56 541.72 0.38365 0.35877
Medical supplies 23.52 102.54 0.00 0.00 0.00 0.00 0.54295 0.33056
Cytostatic agents/biological
agents/biomodulators 28,375.05 21,117.36 32,071.88 27,284.08 26,204.28 17,344.98 0.84182 0.63444
Ø OH
Total costs year 1 36,941.71 15,129.99 52,984.29 28,883.11 33,819.18 24,119.03 0.00707 0.00520
Total costs year 2 28,576.94 24,422.46 36,367.79 31,688.33 32,045.93 23,535.12 0.60112 0.31974
Values represent euros. Ø OH = Overheads. 1 Univariate ANOVA. 2 Student’s t test/Welch’s t test. 
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 In the context of the IVOPAK project, the computed tomography (CT) images (spiral CT 
images of the abdomen and chest) obtained prior to the onset of the palliative first-line 
treatment were generally used to assess the resectability status ( table 1 ). Overall, the CT 
images of more than 50% of the IVOPAK patients were presented at an interdisciplinary 
tumor board prior to initiation of the palliative first-line treatment, although not all of the 
study centers drew support from the interdisciplinary tumor boards.
 In terms of patient characteristics, the IVOPAK collective demonstrates different patient 
characteristics than those of the patient collectives of other major palliative phase III studies 
 [17–21] . For example, the median age of the IVOPAK patient group was 70 years ( table 2 ), 
whereas in the intergroup study comparing irinotecan to oxaliplatin-containing regimens 
(N9741), it was 61 years  [18] ; in the BICC-C study (Randomized, Controlled Trial of Irinotecan 
plus Infusional, Bolus or Oral Fluoropyrimidine), it was 61 years  [17] ; in the OPTIMOX1 study 
(Randomized Study of FOLFOX4 or FOLFOX7 with Oxaloplatin in a Stop-And-Go Fashion in 
Advanced CRC), it was 61 years  [19] , and in the GERCOR study (Groupe Coopérateur Multi-
 Table 5. Drug costs for palliative care at the 3 centers with double-figure recruitment numbers during the first year of treatment
Drug Center A (37 patients) Center B (35 patients) Center C (10 patients) p
value1
total VAT n SD total VAT n SD total VAT n SD
5-FU + folinic acid 415,678.35 560.21 742 103.51 323,193.74 405.00 798 184.74 92,266.93 654.38 141 70.97 0.000
Irinotecan 110,392.37 479.97 230 160.35 314,532.29 933.33 337 326.02 58,111.84 496.68 117 97.90 0.000
Irinotecan mono 0.00 0.00 0 – 0.00 0.00 0 – 0.00 0.00 0 – –
Oxaliplatin 204,218.64 903.62 226 224.06 124,504.41 936.12 133 193.88 21,271.49 686.18 31 8.51 0.164
Cetuximab 2,700.13 1,350.07 2 372.07 291,095.08 1,311.24 222 276.62 25,480.90 1,341.10 19 384.24 0.844
Cetuximab mono 0.00 0.00 0 – 1,342.33 1,342.33 1 – 0.00 0.00 0 – –
Bevacizumab 34,559.56 1,681.99 80 357.94 271,544.31 1,859.89 146 349.56 30,906.09 1,717.01 18 166.89 0.000
Bevacizumab mono 0.00 0.00 0 – 12,492.65 2,498.53 5 0.00 0.00 0.00 0 – –
Panitumumab 0.00 0.00 0 – 33,874.56 2,822.88 12 0.00 0.00 0.00 0 – –
Carboplatin 0.00 0.00 0 – 0.00 0.00 0 – 1,989.91 284.27 7 3.21 –
Docetaxel 0.00 0.00 0 – 0.00 0.00 0 – 4,484.94 747.49 6 0.00 –
Total drug costs 867,549.05 677.77 1,280 339.88 1,372,579.37 829.85 1,654 560.79 234,512.10 691.78 339 334.03 0.000
Values represent euros. 1 Variance analysis, centers A and B; Student’s t test/Welch’s t test.
 Table 6. Drug costs for palliative care at the 3 centers with double-figure recruitment numbers during the second year of 
treatment
Drug Center A (19 patients) Center B (22 patients) Center C (4 patients) p
value1
total VAT n SD total, EUR VAT, EUR n SD total, EUR VAT, EUR n SD
5-FU + folinic acid 180,147.09 549.23 328 137.81 113,711.33 370.40 307 187.97 43,664.46 598.14 73 73.21 0.000
Irinotecan 109,265.27 449.65 243 113.55 180,811.31 966.91 187 211.45 25,094.98 464.72 54 62.10 0.000
Irinotecan mono 0.00 0.00 0 – 2,471.48 1,235.74 2 180.72 0.00 0.00 0 – –
Oxaliplatin 40,285.61 789.91 51 229.83 11,956.26 996.36 12 139.51 8,920.39 892.04 10 120.58 0.004
Cetuximab 89,691.80 1,379.87 65 319.20 183,394.21 1,273.57 144 359.17 0.00 0.00 0 – 0.042
Cetuximab mono 0.00 0.00 0 – 0.00 0.00 0 – 0.00 0.00 0 – –
Bevacizumab 119,736.14 1,478.22 81 518.72 180,380.91 1,939.58 93 533.45 27,137.28 1,596.31 17 34.13 0.000
Bevacizumab mono 0.00 0.00 0 – 14,991.18 2,498.53 6 0.00 0.00 0.00 0 – –
Panitumumab 0.00 0.00 0 – 17,864.64 2,977.44 6 224.61 0.00 0.00 0 – –
Total drug costs 539,125.91 701.99 768 430.60 705,581.32 932.08 757 643.02 104,817.11 680.63 154 347.30 0.000
 Values represent euros. VAT = Value added tax. 1 Variance analysis, centers A and B; Student’s t test/Welch’s t test.
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disciplinaire en Oncologie) on sequential treatment, the median age was 61 years  [20] . 
Furthermore, in the CRYSTAL study (Cetuximab Combined with Irinotecan in First-Line 
Therapy for Metastatic CRC), the median age was 61 years  [7] , and in the FIRE-3 study 
(Randomized Comparison of FOLFIRI plus Cetuximab vs. FOLFIRI plus Bevacizumab First-
Line Treatment of KRAS Wild-Type Metastatic CRC: German AIO Study KRK0306), it was 64 
years  [6] . Although the age parameter does not constitute a prognostic factor  [22] , it is obvious 
that the IVOPAK project did not conduct selective procedures prior to patient enrollment and 
treatment initiation. The relatively advanced age of the IVOPAK patients most probably 
reflects demographic changes in palliative treatment in Germany. The performance status 
(according to the current ECOG index) has been shown in multivariate analysis to be an 
important prognostic factor for the palliative first-line treatment of CRC  [22] . The compara-
tively high percentage of patients (13%) in the IVOPAK study with the unfavorable ECOG 
grade 2 prognostic factor also illustrates that all patients meeting the inclusion criteria were 
enrolled in the IVOPAK study. The frequency of patients with ECOG grade 2 in other phase III 
studies is often in the single-figure range  [4, 6, 7, 23, 24] .
 In terms of other patient characteristics such as gender, primary tumor location and the 
frequency of synchronous or metachronous metastases, the IVOPAK patients did not signifi-
cantly differ from the patient collectives of other phase III studies  [17–21] .
 The main high-grade toxicities (NCI-CTC grade 3/4) in the palliative first-line treatment 
of 103 IVOPAK patients were related to gastrointestinal toxicity, i.e. diarrhea (13%; 95% CI: 
6.2–19.0) and nausea/vomiting (6%; 95% CI: 0.7–9.0), as shown in  table 3 . High-grade hema-
tological toxicity was only observed in isolated cases. All patients of the IVOPAK collective 
were treated with irinotecan-/oxaliplatin-based combined regimens or 5-FU monotherapy 
and the observed NCI-CTC toxicity might be considered somewhat more favorable than the 
higher-grade toxicities arising in the abovementioned first-line studies.
 In the N9741 phase III study, 267 patients were treated first-line with FOLFOX4. High-
grade NCI-CTC toxicities (grade 3/4) in the form of diarrhea (14%) and severe nausea/
vomiting (3%) were observed  [18] . In the OPTIMOX1 phase III study, 311 patients received 
FOLFOX4 as first-line treatment up to disease progression  [19] . In this case, high-grade 
NCI-CTC toxicities (grade 3/4) were observed in 11% (diarrhea) and 5% (nausea/vomiting) 
of patients  [19] . The BICC-C phase III study compared various irinotecan-based combined 
chemotherapy regimens  [17] . In terms of high-grade toxicities, diarrhea occurred in 13.9% 
of the FOLFIRI-treated patients (n = 137) and nausea/vomiting in 17.6%  [17] . The CRYSTAL 
phase III study applied FOLFIRI in 1 treatment arm comprising 599 patients. In this study, 
high-grade toxicity occurred in the form of diarrhea in 14.9% and vomiting in 4.5% of pa-
tients  [7] .
 Colucchi et al.  [21] recruited 360 patients for their phase III study comparing the efficacy 
of FOLFIRI versus FOLFOX4 in first-line treatment. In the FOLFIRI treatment arm, high-grade 
NCI-CTC grade 3/4 toxicities were diarrhea in 10% of patients and nausea/vomiting in 4%, 
whereas in the FOLFOX4 arm, severe NCI-CTC toxicities were seen in 5% (diarrhea) and 3% 
(nausea/vomiting) of patients. High-grade leukocytopenia was observed at a frequency of 3% 
for both schedules  [21] . The EORTC (European Organization for Treatment of Cancer) 40986 
phase III study conducted by Köhne et al.  [25] comprised 430 patients who were enrolled for 
palliative first-line treatment and used in one arm the AIO plus irinotecan regimen [AIO 
regimen: 2-hour infusion of folinic acid (500 mg/m 2 ) followed by 5-FU/2,000 mg/m 2 i.v. as a 
24-hour infusion, on days 1, 8, 15, 22, 29, 36 qd 57 with weekly IRI (80 mg/m 2 ) as 0.5-hour 
infusion]. In this study arm, severe NCT-CTC toxicities (grade 3/4) were diarrhea in 24% and 
nausea/vomiting in 17% of the patients  [25] .
 The favorable overall toxicity observed in the IVOPAK patient collective might be 
explained by the mixed chemotherapeutic approach. On the other hand, it may be attrib-
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utable to the relatively short treatment duration of first-line therapy in some centers, e.g. 
PFS of 4 months at center C, and furthermore, by the comparatively high rate of secondary 
metastasis resection, which frequently entails a short period of first-line chemotherapy 
treatment.
 With a median OS of 25 months, the OS rates achieved by the IVOPAK patients (n = 103) 
can be considered favorable, particularly since only 33 of the IVOPAK patients (32%) had 
received biological agents such as bevacizumab or cetuximab in first-line treatment. The 
IVOPAK patients were treated mainly with either oxaliplatin- or irinotecan-based regimens 
via portacath. In the phase III trial conducted by Colucci et al.  [21] , the patients receiving first-
line FOLFIRI achieved a median OS of 14 months; for the patients receiving FOLFOX4, median 
OS was 15 months. In the N9741 Intergroup phase III study, a median OS of 19.5 months was 
observed in the patient group treated with FOLFOX4  [18] , a result similar to that of the 
OPTIMOX1 study with a median OS of 19.3 months among the patients of the FOLFOX4 arm 
 [19] . In the EORTC 40986 phase III study, AIO plus irinotecan was applied to achieve a median 
OS of 20.1 months  [25] . In the CRYSTAL phase III study, the median OS of the patients treated 
with first-line FOLFIRI (n = 599) amounted to 20 months  [7] . The main reason for the high 
median OS of 25 months achieved in the IVOPAK study might be explained by the relatively 
high number of patients who had undergone secondary metastasis resection (n = 27), as this 
is known to be associated with a favorable OS ( fig. 3 ).
 The patients of the IVOPAK study (n = 103) achieved a PFS of just 7 months with the first-
line treatment. However, as shown in  figure 5 , the PFS achieved by the centers A, B and C 
differed significantly (p < 0.001) between center A (achieving a PFS of 10 months) and center 
C (achieving a PFS of 4 months). The IVOPAK patients may be considered to have been treated 
with a mixed chemotherapeutic approach, receiving different medication types and schedules 
ranging from 5-FU monotherapy to combined chemotherapy and combined chemotherapy 
plus biological agents. Therefore, the main reason for the relatively low median PFS may be 
the limited number of patients (only 32%) who received biological agents during first-line 
treatment within the framework of the IVOPAK study. A similarly unfavorable PFS of 7 months 
was found in the phase III study conducted by Colucci et al.  [21] investigating FOLFIRI versus 
FOLFOX4 as the first-line treatment. The OPTIMOX phase III study focused on the FOLFOX4 
schedule achieved a median PFS of 9.0 months  19] ; the Intergroup N9741 phase III study 
applying FOLFOX4 recorded a PFS of 8.7 months  [18] and the GERCOR study by Tournigand 
et al.  [20] applied FOLFOX6 to achieve a PFS of 8.1 months. The EORTC 40986 phase III study 
patient collective received the AIO regimen plus irinotecan as the first-line treatment and had 
a median PFS of 8.5 months  [25] , whereas the patient group treated with the AIO regimen 
alone achieved a median PFS of solely 6.4 months.
 In the CRYSTAL first-line treatment study, the FOLFIRI group reached a median PFS of 
8.4 months  [7] . The median PFS of 7.0 months achieved in the IVOPAK study – characterized 
by its mixed chemotherapeutic approach – is comparable to the EORTC 40986 study  [25] . The 
relatively high median PFS of 10.0 months in center A might be explained by the relatively 
high rate of secondary metastasis resection of 40% in the palliative patients, the influence of 
which on the PFS rate is represented in  figure 5 . The considerable differences in terms of PFS 
and OS between the abovementioned studies can also be explained by the numerous influ-
encing prognostic factors that may affect both OS and PFS rates  [28] .
 The ORR for the total IVOPAK collective amounted to 38% and 1 patient (1%) achieved 
radiological CR. In the phase III study of Colucci et al.  [21] , the ORR of the subgroup treated 
with the FOLFIRI regimen was 31%, and this was 34% for the subgroup that had received 
FOLFOX4. In the BICC-C study, an ORR of 47% was observed in patients treated with FOLFIRI 
 [17] . In the OPTIMOX1 study, patients of the FOLFOX4 arm had an ORR of 58%  [19] . The 
GERCOR study achieved an ORR of 54% in patients receiving FOLFOX6 as the first-line 
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regimen  [20] , whereas the FOLFIRI-treated patients had an ORR of 56%  [20] . In the CRYSTAL 
study, the ORR of patients with wild-type K-RAS tumors treated with first-line FOLFIRI was 
39%  [7] .
 Secondary metastasis resection subsequent to downsizing of the metastases by first-line 
chemotherapy may make a considerable contribution to achieving the following primary 
treatment objectives.
 Multimodal treatment procedures could increase CR rates (i.e. radiological PR achieved 
by chemotherapy plus secondary metastasis resection). To date, the rate of radiological CR 
that can be obtained by chemotherapy (e.g. FOLFIRI) plus biological agents (e.g. cetuximab 
for proven wild-type K-RAS tumors) amounts to approximately 3%  [7] . Within the IVOPAK 
study, the rate of radiological CR could be increased from 1%, obtained by means of chemo-
therapy treatment alone, to 6% by applying multimodal treatment procedures (i.e. radio-
logical PR plus secondary metastasis resection). Patients with CR during first-line treatment 
achieved the most favorable median survival rates in the N9741 phase III study  [29] . The 
application of the aggressive FOLFOXIRI regimen also resulted in elevated radiological CR 
rates (5%), which were obtained by means of chemotherapy treatment alone  [23] . Due to its 
 Table 7. First-line therapy for CRC within the IVOPAK I study: frequency of the application of specific first-line therapy regimens, 
activities at the interdisciplinary interface and their results
Total cohort Center A Center B Center C Fisher’s 
exact 
test
p value
patients, 
n
regimen n patients, 
n
regimen n patients, 
n
regimen n patients, 
n
regimen n
5-FU 
monotherapy
6/103 
(6%)
AIO
capecitabine
capecitabine+bev.
4
1
1
4/37 
(11%)
AIO 4 0/35 
(0%)
– 0/10
(0%)
– 0.139
Oxaliplatin-
based
combination
chemotherapy
33/103 
(32%)
FOLFOX4
AIO+oxaliplatin
FOLFOX6
Xelox
FUFOX1
11
14
5
2
1
19/37 
(51%)
AIO+oxaliplatin
FOLFOX6
14
5
10/35 
(29%)
FOLFOX4 10 2/10 
(20%)
FUFOX
FOLFOX4
1
1
0.061
Irinotecan-
based 
combination
chemotherapy
31/103 
(30%)
FOLFIRI
AIO+iri.
Xeliri
IFL
14
17
–
–
8/37 
(22%)
FOLFIRI
AIO+iri.
3
5
4/35 
(11%)
FOLFIRI 4 7/10 
(70%)
AIO+iri. 7 0.001
Cetuximab +
chemotherapy
9/103 
(9%)
FOLFIRI+cetuxi.
FOLFOX4+cetuxi.
AIO+iri.+cetuxi.
7
1
1
– – 8/35 
(23%)
FOLFIRI+cetuxi.
FOLFOX4+cetuxi. 07
1
1/10 
(10%)
AIO+iri.+
cetuxi. 1
0.659
Bevacizumab +
chemotherapy
24/103 
(23%)
FOLFIRI+bev.
AIO+iri.+bev.
FOLFOX4+bev.
AIO+oxaliplatin+bev.
16
4
2
2
6/37 
(16%)
AIO+iri.+bev.
AIO+oxaliplatin+bev.
4
2
13/35 
(37%)
FOLFIRI+bev.
FOLFOX4+bev.
12
1
0/10 
(0%)
– 0.020
Secondary
metastasis
resection
27/103 
(26%)
FOLFIRI
FOLFIRI+cetuxi.
FOLFIRI+bev.
AIO+iri.+cetuxi.
AIO+oxaliplatin
FOLFOX6
FOLFOX4
AIO+oxaliplatin+bev.
AIO+iri.+bev.
AIO+iri.
1
2
6
1
5
2
3
2
3
2
15/37
(40%)
AIO+oxaliplatin
FOLFOX6
AIO+oxaliplatin+bev.
FOLFIRI
AIO+iri.
AIO+iri.+bev.
5
2
2
1
2
3
9/35 
(26%)
FOLFOX4
FOLFIRI+bev.
FOLFIRI+cetuxi.
3
4
02
1/10 
(10%)
FOLFOX4 1 0.139
R0 resection 22/27 
(81%)
14/15 
(93%)
– 6/9 
(66%)
0/1 
(0%)
0.054
NED of R0-
resected patients
10/22 
(45%)
– 8/14 
(57%)
– 1/6 
(17%)
– n = 0
(0%)
– 0.157
iri. = Irinotecan; cetuxi. = cetuximab; bev. = bevacizumab; IFL = iri., 5-FU bolus i.v., folinic acid bolus i.v.; AIO = 5-FU/2,600 mg/m2 i.v. simultaneously with sodium 
folinic acid (500 mg/m2) as a 24-hour infusion on days 1, 8, 15, 22, 29, 36 qd 57.
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wide range of higher-grade toxicities and side effects, the FOLFOXIRI regimen is neither 
commonly applied in palliative first-line CRC treatment in Germany, nor does it play a role in 
the first-line treatment schedules of the IVOPAK centers ( table 7 ).
 By obtaining an increase in the number of patients with curative options subsequent to 
R0 resection of secondary metastases, a conversion from the palliative to a curative situ-
ation can be achieved by applying multimodal treatment procedures  [30] . In 10 out of 103 
(10%) palliative patients, the IVOPAK project achieved a fairly long-term conversion from 
a palliative to a curative situation after performing secondary metastasis resection subse-
quent to chemotherapy ( table 7 ). However, the IVOPAK results point to the fact that not all 
of the participating centers were seeking support in the form of interdisciplinary cooper-
ation. An optimized interdisciplinary cooperation should thus be considered as a desirable 
future objective, particularly in view of improved patient care. Aside from the positive long-
term results in the form of NED, the patient cohort treated with multimodal procedures
(n = 27) achieved a median OS of 49 months ( fig. 3 ). This emphasizes the crucial importance 
of interdisciplinary cooperation in terms of improved outcome – even in palliative CRC situ-
ations.
 In the IVOPAK project, resections of secondary metastases were performed subsequent to 
downsizing of distant metastases during first-line treatment only. This might be explained by 
the fact that established second-line schedules have yielded relatively low response rates  [20, 
24, 26] . Second-line treatment schedules with higher response rates, e.g. FOLFIRI plus aflibercept 
(response rate:  ∼ 20%), could give rise to a change or secondary metastasis resection during 
second-line chemotherapy  [31] . Study results on this topic remain to be seen. The IVOPAK 
project confirms that secondary metastasis resections were most frequently applied to patients 
a b c
d fe
 Fig. 7. Regular follow-up evaluations with presentation of CT images to the interdisciplinary tumor board. 
Evaluations were conducted at 8-week intervals during first-line treatment (CCS) .  a Prechemotherapy (June 
27, 2007).  b After the first cycle (September 11, 2007; 2 months of therapy).  c After the second cycle; PR 
(November 13, 2007; 4 months of therapy).  d After the third cycle; confirmed PR (January 15, 2008; 6 months 
of therapy).  e After the fourth cycle (March 25, 2008; 8 months of therapy).  f Postoperative, last follow-up 
(11/2011); time after hemihepatectomy (right) + segment resection III (R0); pathohistological CR. 
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with liver-only metastases  [32] . However, it should be stated that patients with other meta-
static locations – e.g. lung-only or peritoneal carcinomatosis metastases, or patients with 
combined distant metastases – should not, in principle, be excluded from secondary metastasis 
resection. In cases where surgery is possible, the CT scans of the affected patients should be 
presented to an interdisciplinary tumor board. Additionally, promising results could be achieved 
by regularly presenting the CT scans to an interdisciplinary tumor board (Continuous Check 
Strategy, CCS;  fig. 7 ) during the course of treatment, e.g. every 2 months. Such a strategy would 
enable the most favorable time point at which to perform a possible secondary metastasis 
resection to be identified. The participating IVOPAK centers were not restricted by any rules or 
regulations in terms of treatment decisions. In center A, a CCS ( fig. 6 ) was regularly carried out 
due to positive experiences gained in previous studies  [11, 27] .
 This may explain the relatively high rate of secondary metastasis resections of 40% in 
patients with primarily nonresectable distant metastases. Moreover, both the favorable 
median OS of 27 months and the favorable PFS of 10 months in center A might be explained 
by considering the high rate of secondary metastasis resections (40%) and the influence of 
this on OS and PFS ( fig. 3 ). Since only 16% of patients in center A received biological agents 
in first-line treatment, the influence of biological agents on OS and PFS in center A is likely to 
be limited ( table 7 ), and this area of treatment requires optimization.
 The favorable outcome in terms of median OS of the IVOPAK patient group treated in a 
multimodal context clearly surpasses the median OS of the patient group treated with chemo-
therapy alone ( fig. 3 ). The improved outcome of the multimodal group is comparable with 
the outcome results of other studies. For example, in a retrospective analysis of patients with 
isolated peritoneal carcinomatosis of CRC, Elias et al.  [33] demonstrated that 48 patients 
who had received palliative chemotherapy alone had a median survival of 23.9 months, 
whereas 48 patients who had been treated in a multimodal context (i.e. peritonectomy plus 
hyperthermic intraperitoneal chemotherapy with oxaliplatin) achieved a median survival of 
62.7 months. After a median follow-up of 95.7 months, the 5-year survival rate was 13 versus 
51%, thus demonstrating a clear advantage of the multimodal treatment over chemotherapy 
alone. Out of 119 patients suffering from nonresectable liver metastases of CRC who had 
been enrolled into a randomized EORTC phase II study, 59 patients received systemic 
combined chemotherapy based on 5-FU/folinic acid and oxaliplatin plus/minus bevaci-
zumab up to tumor progression and 60 patients received systemic chemotherapy with radio-
frequency ablation plus/minus secondary metastasis resection  [34] . Median OS was 40.5 
months for the patient group receiving systemic treatment and 45.3 months for the patient 
group treated according to multimodal procedures. The 3-year PFS rates were 27.6 and 
10.6% for the multimodal and systemic treatments, respectively. Kopetz et al.  [35] retro-
spectively investigated the outcome of 2,470 patients with metastatic CRC and assessed a 
continuous improvement in terms of median survival from 2000 to 2006. During the obser-
vational period between 2004 and 2006, median survival was 29.3 months. This outcome is 
comparable to the OS of the total collective observed in the IVOPAK study. In the authors’ 
opinion, the increased application of new chemotherapeutical agents and incremental 
increases in the rate of secondary liver metastasis resections gave rise to this positive result. 
The outcome of the IVOPAK study demonstrates that remarkable improvements are 
achievable in palliative situations, on the condition that multimodal treatment procedures, 
close interdisciplinary cooperation, and appropriate secondary metastasis resection 
methods are adhered to. By observing the aforementioned considerations, the multimodal 
patient group of the IVOPAK study achieved a median OS of 49 months ( fig. 3 ) and a median 
PFS of 18 months ( fig. 6 ).
 With a median survival of 47 months in the multimodal patient group (n = 34), the 
outcome in the GERCOR study conducted by Tournigand et al.  [20] presents similar results. 
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More than ever, it is of vital importance to implement the European Society for Medical 
Oncology (ESMO) Guidelines, which recommend that ‘The management of CRC must be a 
multimodal approach by an experienced multidisciplinary expert team’  [3] .
 The cost of care for palliative treatment of CRC in all IVOPAK patients (n = 103) during 
the first and second years has been calculated and published previously  [9] . The major cost 
drivers in palliative treatment were drug costs (cytostatic drugs plus biological agents and 
biomodulators) in the IVOPAK collective, which amounted to 4,298,327.86  [9] . This corre-
sponds to 70% of the total accumulated costs of palliative care  [9] . Comparative analyses 
in terms of cost-of-care evaluations for palliative CRC treatment in Germany still remain to 
be accomplished. A systematic international review published by Kriza et al.  [36] demon-
strated that the initial and terminal phases of CRC care are the most expensive, with 
continuing treatment being the most costly phase. A cost-of-care evaluation in French 
palliative CRC patients demonstrated an increase in costs from 17,596 to 35,099 that was 
related to the deteriorating stage of disease, i.e. from Union for International Cancer Control 
(UICC) stage I to UICC stage IV  [37] . In this cost analysis, ‘medical purchases’ ranked second 
in terms of expenditures. This is explained by the fact that the proportion of patients in 
UICC stage IV who required mainly systemic treatment was relatively low. In addition, this 
French analysis evaluated costs during the first year after diagnosis only. A review on costs 
of care in CRC ascertained a trend for rising costs, which is related to the increasing appli-
cation of biological agents in CRC treatment  [36] . Owing to the similar number of enrolled 
patients in centers A (n = 37) and B (n = 35), the figures from these 2 centers would appear 
to be simply comparable. In the first year of treatment, drug costs (cytostatic agents, 
biological agents and biomodulators) were the main cost drivers ( table 4 ). Significant 
differences were observed in terms of drug costs between centers A and B during the first 
and second years of treatment ( tables 5 ,  6 ). The treatment preferences and peculiarities
of centers A and B were also reflected by differences in drug costs and applied agents ( ta-
bles 5 ,  6 ).
 The costs reflect the preferences of the centers for particular agents and schedules. For 
example, 63% of center B patients received biological agents during first-line treatment. 
According to previously published studies, biological agents were mostly combined with 
FOLFIRI  [6] and these combinations (i.e. FOLFIRI plus biological agents) frequently lead to 
long treatment durations (i.e. a high number of applications). Therefore, total costs for irino-
tecan and biologicals were significantly higher in center B. In comparison, center A produced 
significantly higher costs for 5-FU, folinic acid and oxaliplatin than center B. Center A often 
preferred an oxaliplatin-based combined chemotherapy as the first-line treatment and mainly 
applied weekly infusion regimens in accordance with the AIO schedule ( table 7 ). The AIO 
regimen generally comprises relatively high doses of 5-FU and folinic acid as compared to the 
biweekly schedules of FOLFIRI or FOLFOX4, for example. Apart from the preferences for 
specific schedules, the high rate of secondary metastasis resections in center A ( table 7 ), 
which were mostly performed during first-line therapy (i.e. during the first year of treatment), 
represents a major factor contributing to the significant differences in costs between centers 
A and B.
 In center A, secondary metastasis resections were performed in 15 out of 37 patients 
(40%) and resulted in discontinuation of the formerly applied medication. Of the 14 
R0-resected patients, 8 (57%) remained NED and required no more drugs. This was asso-
ciated with saving drug costs and thus limiting the main cost driver. The patients who main-
tained an NED status – 8 out of the 15 secondarily resected patients (53%) in center A – also 
contributed to cost limitations during the second year of palliative treatment. This is a possible 
further reason for the observed differences in costs ( table 5 ).
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 Conclusion 
 Palliative treatment of metastatic CRC in the IVOPAK study was mostly performed in 
accordance with S3 treatment guidelines  [2] . However, the clinical treatment reality in 
Northern Bavaria clearly requires optimization, which would potentially be achievable by the 
following:
 • An increased use of approved and validated biological agents in first-line treatment. In 
the IVOPAK study, only 32% of patients received biological agents during first-line 
treatment. 
 • Region-wide accessibility of all oncological centers to an interdisciplinary tumor board 
with experience in metastasis surgery could optimize the rate of secondary metastasis 
resections and thus patient outcome. 
 • An improved implementation of sequential treatment, which has been made even more 
complex by the approval of new agents  [31, 38] . 
 • IVOPAK study illustrates that vital prognostic improvements in palliative treatment are 
obtained by close interdisciplinary cooperation. 
 • The patients of the center with the closest and most intensive interdisciplinary cooper-
ation in terms of secondary metastasis resection had the most favorable outcome and 
their treatment was also associated with the lowest costs. In general, considerable differ-
ences – both in terms of outcome and quality of care – have been demonstrated between 
the centers with double-figure enrolment numbers, and these issues are to be improved 
in a future project. 
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